The position of the AUG start codon in MFG-based γ-retroviral vectors has a dramatic effect on translation-dependent protein expression

Journal of Gene Medicine

Volumn 13, Issue 9, 2011, Pages 478-486

  Frankel, Timothy L ^a   Zhang, Ling ^a   Burns, William R ^a   Zheng, Zhili ^a   Morgan, Richard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Kozak sequence; Mutational analysis; Retroviral vector; TCR gene transfer; Untranslated region

Indexed keywords

GAMMA RETROVIRUS VECTOR; MSGV1 VECTOR; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CONSENSUS SEQUENCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; START CODON; TRANSLATION INITIATION;

ANIMALS; BASE SEQUENCE; CODON, INITIATOR; GENE EXPRESSION REGULATION; GENE ORDER; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; LYMPHOCYTES; MICE; MOLECULAR SEQUENCE DATA; MOLONEY MURINE LEUKEMIA VIRUS; PROTEIN BIOSYNTHESIS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RETROVIRIDAE; RNA, MESSENGER; TRANSDUCTION, GENETIC;

MOLONEY MURINE LEUKEMIA VIRUS;

EID: 80053413630     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1599     Document Type: Article

References (40)

1. Kohn DB, Candotti F. Gene therapy fulfilling its promise. N Engl J Med 2009; 360: 518-521.
2. Baum C, Schambach A, Bohne J, et al. Retrovirus vectors: toward the plentivirus? Mol Ther 2006; 13: 1050-1063.
3. Flotte TR. Gene therapy: the first two decades and the current state-of-the-art. J Cell Physiol 2007; 213: 301-305.
4. Dropulic B. Genetic modification of hematopoietic cells using retroviral and lentiviral vectors: safety considerations for vector design and delivery into target cells. Curr Hematol Rep 2005; 4: 300-304.
5. Hawley RG. Progress toward vector design for hematopoietic stem cell gene therapy. Curr Gene Ther 2001; 1: 1-17.
6. Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-932.
7. Cepko CL, Roberts BE, Mulligan RC. Construction and applications of a highly transmissible murine retrovirus shuttle vector. Cell 1984; 37: 1053-1062.
8. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
9. Ohashi T, Boggs S, Robbins P, et al. Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector. Proc Natl Acad Sci USA 1992; 89: 11332-11336.
10. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 1995; 92: 6733-6737.
11. Jaffee EM, Dranoff G, Cohen LK, et al. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 1993; 53: 2221-2226.
12. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
13. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14: 1264-1270.
14. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
15. Hawley RG, Lieu FH, Fong AZ, et al. Versatile retroviral vectors for potential use in gene therapy. Gene Ther 1994; 1: 136-138.
16. Hughes MS, Yu YY, Dudley ME, et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther 2005; 16: 457-472.
17. Krall WJ, Skelton DC, Yu XJ, et al. Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells. Gene Ther 1996; 3: 37-48.
18. Kim SH, Yu SS, Park JS, et al. Construction of retroviral vectors with improved safety, gene expression, and versatility. J Virol 1998; 72: 994-1004.
19. Hildinger M, Abel KL, Ostertag W, et al. Design of 5' untranslated sequences in retroviral vectors developed for medical use. J Virol 1999; 73: 4083-4089.
20. Kozak M. Point mutations close to the AUG initiator codon affect the efficiency of translation of rat preproinsulin in vivo. Nature 1984; 308: 241-246.
21. Kozak M. An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987; 15: 8125-8148.
22. Kozak M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 1986; 44: 283-292.
23. Kozak M. Pushing the limits of the scanning mechanism for initiation of translation. Gene 2002; 299: 1-34.
24. Kozak M. Regulation of translation via mRNA structure in prokaryotes and eukaryotes. Gene 2005; 361: 13-37.
25. Aiuti A. Advances in gene therapy for ADA-deficient SCID. Curr Opin Mol Ther 2002; 4: 515-522.
26. Heemskerk B, Liu K, Dudley ME, et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther 2008; 19: 496-510.
27. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114: 535-546.
28. Zhang Y, Frohman MA. Using rapid amplification of cDNA ends (RACE) to obtain full-length cDNAs. Methods Mol Biol 1997; 69: 61-87.
29. Li X, Zhao X, Fang Y, et al. Generation of destabilized green fluorescent protein as a transcription reporter. J Biol Chem 1998; 273: 34970-34975.
30. Wargo JA, Robbins PF, Li Y, et al. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol Immunother 2009; 58: 383-394.
31. Frankel TL, Burns WR, Peng PD, et al. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J Immunol 2010; 184: 5988-5998.
32. Morgan RA, Dudley ME, Yu YY, et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 2003; 171: 3287-3295.
33. Matsumoto K, Wassarman KM, Wolffe AP. Nuclear history of a pre-mRNA determines the translational activity of cytoplasmic mRNA. EMBO J 1998; 17: 2107-2121.
34. Fong YW, Zhou Q. Stimulatory effect of splicing factors on transcriptional elongation. Nature 2001; 414: 929-933.
35. Reed R, Hurt E. A conserved mRNA export machinery coupled to pre-mRNA splicing. Cell 2002; 108: 523-531.
36. Frankel TL, Burns WR, Peng PD, et al. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J Immunol 2010; 184: 5988-5998.
37. Kozak M. An analysis of vertebrate mRNA sequences: intimations of translational control. J Cell Biol 1991; 115: 887-903.
38. Vassalli P. The pathophysiology of tumor necrosis factors. Ann Rev Immunol 1992; 10: 411-452.
39. Robertson MJ, Ritz J. Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist 1996; 1: 88-97.
40. Kammula US, Marincola FM, Rosenberg SA. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst 2000; 92: 1336-1344.